Modality
ERT
MOA
TNFi
Target
PSMA
Pathway
Epigenetic
Ewing Sarcoma
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
Mar 2023
→ Mar 2031
Phase 2Current
NCT03367456
629 pts·Ewing Sarcoma
2023-03→2031-03·Completed
629 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-135.0y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Complet…
Catalysts
Ph3 Readout
2031-03-13 · 5.0y away
Ewing Sarcoma
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03367456 | Phase 2/3 | Ewing Sarcoma | Completed | 629 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Doxacagene | Sanofi | Approved | PSMA | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Ribozanubrutinib | Genmab | Approved | GPRC5D |